RxDoctor Payments Data

Shemina Ransom, NP

Gerontology · Jackson, MSNPI 1518457928

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.

$2,674in general payments, 2019–2025

Across 142 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$461
  • Novo Nordisk$368
  • Dexcom, Inc.$336
  • Lilly USA, LLC$263
  • Amgen$189
  • Insulet Corporation$106
  • plus $952 from 19 others

What the payments were for

  • Food & beverage$2,674100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,674 in reported general payments places this provider in the 75th percentile of 66 gerontology providers in Mississippi.

See all gerontology providers in Mississippi

Medicare billing

Part B allowed, 2024
$17,512
Medicare patients
77
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$91,188
JardianceEmpagliflozin42$33,920
RybelsusSemaglutide19$31,377
Victoza 3-PakLiraglutide34$27,895
TrulicityDulaglutide24$27,861
JanuviaSitagliptin Phosphate40$24,284
TradjentaLinagliptin25$18,398
Tresiba Flextouch U-100Insulin Degludec24$14,234
Novolog FlexpenInsulin Aspart78$13,494
Lantus SolostarInsulin Glargine,hum.Rec.Anlog94$11,518
Tresiba Flextouch U-200Insulin Degludec12$11,119
Victoza 2-PakLiraglutide15$7,712
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,412
Humalog Kwikpen U-100Insulin Lispro32$5,098
Humulin R U-500 KwikpenInsulin Regular, Human11$4,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$368$122,56595 claims
Boehringer IngelheimJardiance, Tradjenta$77$52,31867 claims
Lilly USA, LLCTrulicity$263$27,86124 claims
MerckJanuvia$11$24,28440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 66 gerontology providers in Mississippi.

Other gerontology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →